Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

26.92B

Market cap26.92B

Price-Earnings ratio

20.74

Price-Earnings ratio20.74

Dividend yield

—

Dividend yield—

Average volume

846.62K

Average volume846.62K

High today

$187.25

High today$187.25

Low today

$181.68

Low today$181.68

Open price

$182.18

Open price$182.18

Volume

758.72K

Volume758.72K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$110.04

52 Week low$110.04

Stock Snapshot

Biogen(BIIB) stock is priced at $187.25, giving the company a market capitalization of 26.92B. It carries a P/E multiple of 20.74.

On 2026-03-19, Biogen(BIIB) stock moved within a range of $181.68 to $187.25. With shares now at $187.25, the stock is trading +3.1% above its intraday low and 0.0% below the session's peak.

Trading activity shows a volume of 758.72K, compared to an average daily volume of 846.62K.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

BIIB News

TipRanks 8h

Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has launched a Phase 3 trial called “A Phase 3 Study With an Open-La...

TipRanks 8h

Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has completed a Phase 1 study titled “A Phase 1, Open-Label Study to...

Simply Wall St 3d

Biogen Legal Chief Exit Puts Focus On Valuation Gap And Returns

Biogen announced that Chief Legal Officer Susan H. Alexander will depart at the end of May 2026. The company has begun a search for her successor to lead its l...

Analyst ratings

56%

of 36 ratings

Buy

41.7%

Hold

55.6%

Sell

2.8%

More BIIB News

TipRanks 3d

Biogen price target raised to $150 from $143 at HSBC

HSBC analyst Morten Herholdt raised the firm’s price target on Biogen (BIIB) to $150 from $143 and keeps a Reduce rating on the shares. The firm says the uncert...

Simply Wall St 6d

Does New Once-Yearly SMA Data And Phase 3 Plan Change The Bull Case For Biogen?

In early March 2026, Biogen reported additional Phase 1b data for its investigational once-yearly SMA therapy salanersen, showing sustained safety, slowing of n...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.